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Results:
In all plans, the dosimetric coverage of the target volume and the dose to OARs were within clinical limits. The coverage of the PTV were disclosed: CICRU = 1.0(0.9-1.1); CI65 = 0.7(0.4-1.0); HI = 0.3(-0.3-0.5); Dmin/Dmax = 0.6(0.5-0.7); D2%, = 64.6(47.5-71.3)Gy; D98% = 47.2(39.5-68.6)Gy; )Gy. In the 3DCRT Plans, the mean dose in the PTV was on average, 3 Gy higher than dynamic techniques; MU and irradiation time were by the factor of 2-3 higher in the dynamic techniques. Dose to the OARs for the 1st and 2nd patient is as bellows: Dmedi, ipsilat. lung = 4.9 (3.2-8.8)Gy; Dmax, esophagus = 7.7(0.4-16.1)Gy. V35Gy, rips = 10(0.6-43.7). For the 3rd one: Dmedi., ipsilat. lung = 8.3(6.8-10)Gy; Dmedi.,contralat. lung = 2.3(1.4-4.7)Gy Dmax, esophagus=20.7(11.3-27.7)Gy. Picture shows the Dmax for the spinal cord.
Conclusion:
All irradiation techniques were applicable for clinical use, the resulting dose distribution were quite similar. By comparison, the statistically significant differences between the users were greater than the differences between the techniques. This demonstrate that strict constrains and works like the DEGRO reference paper (Guckenberger et al) are necessary to homogenize the SBRT planning at a national level. This study reports the results of the irradiation planning for the treatment of NSCLC with SBRT depends largely on the user. The aims of this study were to develop dose target constraints for re-irradiation of the sciatic nerve, and to assess the impact of nerve-sparing optimisation on target volume coverage and OAR sparing with stereotactic radiotherapy techniques.
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Material and Methods:
Cumulative dose constraints for reirradiation were derived assuming prior pelvic radiotherapy of 50Gy (EQD2) and allowing nerve recovery values of 50% and 100%. Treatment plans were produced for 10 patients with recurrent gynaecological cancer delivering 30 Gy in 5 fractions. Two normalisation methods were assessed: ICRU 83 type normalisation and prescription (ICRU); and stereotactic radiosurgery convention of prescribing to the isodose covering 95% PTV allowing maximum doses of ~125% (SRS). For each method, plans were optimised with and without sciatic nerve sparing targets. Sciatic nerve roots were contoured from sacral foramina until the nerve exits the pelvis. Nerve sparing plans were optimised to minimize dose to nerve PRV while maintaining PTV coverage. Doses to GTV, PTV, OAR and sciatic nerve were compared.
Results: All 40 plans met the PTV targets with >95% PTV coverage by the specified isodose. The sciatic nerve was involved in 3 patients, close proximity (<5 mm) in 4 patients and more than 5 mm distant from PTV in 3 patients. The dose targets were Dmax 32 Gy when there was nerve involvement and 21.9 Gy when the nerve was distant from tumour. For all patients, the sciatic nerve dose was reduced with each technique: median Dmax with ICRU from 28.8 Gy to 22.3 GY and with SRS from 28.7 Gy to 19.9 Gy. For patients with overt nerve involvement, median Dmax was reduced from 34.9 Gy to 32.1 Gy with SRS. Nerve sparing was achieved without significantly decreasing GTV mean doses or increasing bowel doses.
Conclusion:
The sciatic nerve should be an OAR for reirradiation of sidewall recurrence. Optimisation using a sciatic nerve PRV can significantly reduce dose to nerve by up 40% (EQD2-2) while having minimal effect on GTV coverage or bowel doses. Feasible dose targets depend on proximity of nerve to GTV and clinical scenario. Purpose or Objective: Over the last half century we have seen remarkable improvements in the survival of pediatric cancer patients. Therefore, the impact of cancer and its treatment must be assessed. Furthermore, the radiotherapy technique must be well selected in order to minimize the secondary effects. Since hearing loss is a common late effect of radiotherapy, the purpose of this study was to compare three different treatment techniques and to evaluate the dose to the cochleas and supretentorial brain, in children treated with radiotherapy for medulloblastoma.
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Material and Methods:
A total of 121 children were treated in our department with radiotherapy for CNS tumors, between January 2000 and December 2014. Those who were diagnosed with medulloblastoma were included. A total of 29 children fulfilled these criteria. The adopted treatment plan consisted of a first phase with three-dimensional conformal radiotherapy (3D-CRT) to the craniospinal region (prescribed doses from 23.4 to 36.0 Gy) followed with a boost to the PTV (posterior fossa/tumor bed) with prescribed doses of 18.0 or 31.6 Gy depending on the clinical risk-group, high or standard risk respectively . For each child, three different treatment plans were prepared for the boost phase: one with conventional 2 parallel opposed fields (CRT), one more complex with 3D conformal radiotherapy (3D-CRT) and another with IMRT. The original plans delivered to the patients were not considered in this study because treatment techniques have been changing since 2000 and were not uniform within the selected group. All plans assured PTV coverage according to ICRU 83 criteria. Cochleas and supratentorial brain mean doses, as organs , were analyzed using QUANTEC values and compared for each plan.
Results: Among 29 children, 22 were males. The median age at diagnosis was 8.66 years. At the beginning of treatment, their age range from 3.26 to 15.47 years old. The average mean dosesto the OAR analyzed are presented in Table 1 . 
Purpose or Objective:
This work is to present the treatment planning workflow and delivery technique for the first application of linac based spatially fractionated mini-beam radiotherapy within a clinical trial of canine brain tumor treatments. The motivation for this investigation originates from work performed using synchrotron generated microbeams (MRT) which have shown promising results in preserving brain architecture while killing tumor cells. Spatial fractionation of radiation using arrays of parallel micro-planar beams is a developing technique with many unknowns and limitations. To further research this technique and to potentially enable MRT for human treatments, a minibeam collimator has been designed for use with a linac and a Monte Carlo (MC) beam model has been commissioned for clinical treatment planning.
Material and Methods:
Patient population was selected from client-owned canines with spontaneously occurring brain tumors. Patients were placed under general anesthesia and positioned prone within stereotactic immobilization equipment during imaging and treatment delivery. CT and MRI images were used for contouring. The planning technique utilized an arrangements of static mini-beams. Beam angles were chosen such that the treatment depth was within 20% for each beam to minimize beam broadening with depth and blurring of the peak and valley doses. Beam apertures were defined with the MLC leaves set 3 mm back from the PTV. The mini-beam collimated dose distributions were calculated to a statistical uncertainty of ±1.0 % within a voxel size of 0.5 mm. Beam weighting was equalized and the plan normalized such that the prescription dose was delivered to an ICRU dose reference point within the PTV. Deliver quality assurance (DQA) was performed by measuring the absolute dose from each beam using an ion chamber within a solid water phantom.
Results: Contouring and beam arrangement, which included MLC placement, was performed within the clinical treatment planning system (TPS). The DICOM plan was then exported to the MC treatment planning system for mini-beam dose calculation. The distribution was reviewed and DVHs assessed for normal tissue tolerances. The final step was to transcribe the calculated MUs back to the original TPS. Planning turnaround time was 2 days. The MC calculations were initiated overnight at the end of day 1. Day 2 was spent reviewing the plan, generating the DQA plan, and finalizing the treatment parameters into the record-and-verify system (RVS). DQA output measurements of the treatment fields agreed with the calculated dose to within 1.5%. An image of the patient dose distribution and setup is shown in figure 1.
Conclusion:
A workflow for mini-beam treatments that includes the planning technique, MC dose calculation method, DQA process, and data integration into a RVS has been established. This clinical dataset represents the first treatment planning study of linac based mini-beam patients. Purpose or Objective: The aim of this study is to investigates different strategies in choosing, in a mathematical way, the structure set that best fit a Dose Painting (DP) distribution, based on ADC maps, to be submitted to the optimization process within the TomoTherapy TPS.
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Material and Methods: Hypofractionated Stereotactic
Radiation Therapy plans in 5 fractions of intracranial GBM for six patients were retrospectively realized.
